Patents by Inventor Hemant Kumar Singh
Hemant Kumar Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10815227Abstract: The present invention relates to processes for the preparation of Filgotinib. The present invention relates to novel processes for the preparation of filgotinib. The present invention also relates to novel intermediates for the preparation of filgotinib.Type: GrantFiled: August 23, 2019Date of Patent: October 27, 2020Assignee: CADILA HEALTHCARE LIMITEDInventors: Sanjay Jagdish Desai, Kuldeep Natwarlal Jain, Naitik Bharatbhai Patel, Hemant Kumar Singh
-
Publication number: 20200062744Abstract: The present invention relates to processes for the preparation of Filgotinib. The present invention relates to novel processes for the preparation of filgotinib. The present invention also relates to novel intermediates for the preparation of filgotinib.Type: ApplicationFiled: August 23, 2019Publication date: February 27, 2020Inventors: Sanjay Jagdish DESAI, Kuldeep Natwarlal JAIN, Naitik Bharatbhai PATEL, Hemant Kumar SINGH
-
Patent number: 10544109Abstract: The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of expensive chemicals, hazardous reagents or tedious purification techniques. Invention also provides novel intermediate useful for preparation of desired compound in high purity.Type: GrantFiled: September 1, 2016Date of Patent: January 28, 2020Assignee: Fresenius Kabi Oncology Ltd.Inventors: Hemant Kumar Singh, Sandeep Kumar, Ghanashyam Madhukar Sonavane, Vishal Handa, Chandan Kumar Gupta, Sunil Sanghani, Potru Sivaiah, Saswata Lahiri, Walter Cabri, Nitin Gupta
-
Publication number: 20180324001Abstract: The present invention disclosure relates to a system for monitoring deterministic characteristics of a safety critical network. The system has an Ethernet switch associated to a processor-memory unit that runs deterministic unit functionality or a multi-core system in which one or more cores have Ethernet switch functionality and one or more dedicated cores have deterministic unit functionality, a communication channel between the Ethernet switch and the processor-memory unit associated to a deterministic unit or the inter-core communication channel between the core/s running Ethernet switch functionality and the core/s running deterministic unit functionality and an Ethernet virtual connection (EVC) between adjacent switches through which the associated deterministic units communicate with each other.Type: ApplicationFiled: April 8, 2016Publication date: November 8, 2018Inventors: Vipin TYAGI, Shishir SHROTRIYA, Prashant CHUGH, Deepika NAGPAL, Hemant Kumar Singh CHAUHAN
-
Publication number: 20180244635Abstract: The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of expensive chemicals, hazardous reagents or tedious purification techniques. Invention also provides novel intermediate useful for preparation of desired compound in high purity.Type: ApplicationFiled: September 1, 2016Publication date: August 30, 2018Applicant: FRESENIUS KABI ONCOLOGY LTD.Inventors: Hemant Kumar SINGH, Sandeep KUMAR, Ghanashyam Madhukar SONAVANE, Vishal HANDA, Chandan Kumar GUPTA, Sunil SANGHANI, Potru SIVAIAH, Saswata LAHIRI, Walter CABRI, Nitin GUPTA
-
Patent number: 9440979Abstract: An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.Type: GrantFiled: July 18, 2013Date of Patent: September 13, 2016Assignee: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Saswata Lahiri, Nitin Gupta, Hemant Kumar Singh, Nilendu Panda, Vishal Handa, Azim Abul, Chandan Kumar Gupta, Sunil Sanghani, Ghanashyam Madhukar Sonavane
-
Publication number: 20150297738Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: June 29, 2015Publication date: October 22, 2015Inventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20150183789Abstract: An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.Type: ApplicationFiled: July 18, 2013Publication date: July 2, 2015Applicant: Fresenius Kabi Oncology LimitedInventors: Saswata Lahiri, Nitin Gupta, Hemant Kumar Singh, Nilendu Panda, Vishal Handa, Azim Abul, Chandan Kumar Gupta, Sunil Sanghani, Ghanashyam Madhukar Sonavane
-
Publication number: 20140088298Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxy-yalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: March 27, 2014Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20140073779Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: March 13, 2014Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Patent number: 8524893Abstract: Novel intermediates, process for their preparation and their use in the preparation of therapeutically effective antineoplastic agents, in particular Temsirolimus of formula (I).Type: GrantFiled: January 28, 2011Date of Patent: September 3, 2013Assignee: Fresenius Kabi Oncology LimitedInventors: Nitin Gupta, Vishal Handa, Abir Kumar Pal, Hemant Kumar Singh, Saswata Lahiri, Sushil Kumar Dubey
-
Publication number: 20130211060Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxy-yalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: August 15, 2013Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacker, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20130184455Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.Type: ApplicationFiled: July 11, 2011Publication date: July 18, 2013Applicant: Fresenius Kabi Deutschland GmbHInventors: Helmut Knoller, Dominik Heckmann, Frank Hacket, Norbert Zander, Frank Nocken, Saswata Lahiri, Nitin Gupta, Sunil Sanghani, Azim Abul, Hemant Kumar Singh, Sandeep Grewal, Sandeep Kaur
-
Publication number: 20120277297Abstract: The present invention relates to pharmaceutical composition comprising the naturally occurring compounds selected from (±) Marrnesin, Columbianetin, Dihydroxanthyletin and substituted coumarin derivatives of 7-allyloxy coumarin, 7-benzyloxy coumarin, 7 -methoxycoumarin, 7-acetyloxy coumarin, 4-methyl-7-hydroxy coumarin and 4-methyl-7-acetyloxy coumarin. The said compositions possess a high degree of acetylcholinesterase inhibitory (AChE) property.Type: ApplicationFiled: April 30, 2012Publication date: November 1, 2012Applicant: Council of Scientific and Industrial ResearchInventors: Janaswamy Madhusudana Rao, Bhimapaka China Raju, Pullela Venkata Srinivas, Katragadda Suresh Babu, Jhillu Singh Yadav, Kondapuram Vijaya Raghvan, Hemant Kumar Singh, Chandiswar Nath
-
Patent number: 8188143Abstract: The present invention relates to pharmaceutical composition comprising the naturally occurring compounds selected from (±) Marmesin, Columbianetin, Dihydroxanthyletin and substituted coumarin derivatives of 7-allyloxy coumarin, 7-benzyloxy coumarin, 7-methoxy coumarin, 7-acetyloxy coumarin, 4-methyl-7-hydroxy coumarin and 4-methyl-7-acetyloxy coumarin. The said compositions posses a high degree of acetylcholinesterase inhibitory (AChE) property.Type: GrantFiled: March 20, 2007Date of Patent: May 29, 2012Assignee: Council of Scientific and Industrial ResearchInventors: Janaswamy Madhusudana Rao, Bhimapaka China Raju, Pullela Venkata Srinivas, Katragadda Suresh Babu, Jhillu Singh Yadav, Kondapuram Vijaya Raghvan, Hemant Kumar Singh, Chandiswar Nath
-
Publication number: 20110184167Abstract: Novel intermediates, process for their preparation and their use in the preparation of therapeutically effective antineoplastic agents, in particular Temsirolimus of formula (I).Type: ApplicationFiled: January 28, 2011Publication date: July 28, 2011Applicant: Fresenius Kabi Oncology LimitedInventors: Nitin Gupta, Vishal Handa, Abir Kumar Pal, Hemant Kumar Singh, Saswata Lahiri, Sushil Kumar Dubey
-
Patent number: 6896901Abstract: The present invention provides new uses of Gugulipid, an ethyl acetate extract of the resin of the plant Comiphora wighitii, for controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin and a method of preparing Gugulipid by agitating the resin in shake flask assembly or sonicating assembly and preparing a solid or a creamy dosage forms.Type: GrantFiled: December 22, 2000Date of Patent: May 24, 2005Assignee: Council of Scientific & Industrial ResearchInventors: Ram Pratap, Raghwendra Pal, Satyawan Singh, Girja Shankar, Chandeshwar Nath, Hemant Kumar Singh, Depak Raina, Arwind Kumar Srivastava, Anil Kumar Rastogi, Puvvada Sri Ramachandra Murthy, Sudhir Srivastava, Onkar Prasad Asthana, Narenda Singh, Nitya Nand
-
Publication number: 20030099729Abstract: The present invention provides new uses of Gugulipid, an ethyl acetate extract of the resin of the plant Comiphora wighitii, for controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin and a method of preparing Gugulipid by agitating the resin in shake flask assembly or sonicating assembly and preparing a solid or a creamy dosage forms.Type: ApplicationFiled: December 20, 2002Publication date: May 29, 2003Inventors: Ram Pratap, Raghwendra Pal, Satyawan Singh, Girja Shankar, Chandeshwar Nath, Hemant Kumar Singh, Depak Raina, Arwind Kumar Srivastava, Anil Kumar Rastogi, Puvvada Sri Ramachandra Murthy, Sudhir Srivastava, Onkar Prasad Asthana, Narendra Singh, Nitya Nand
-
Publication number: 20020119206Abstract: The present invention provides new uses of Gugulipid, an ethyl acetate extract of the resin of the plant Comiphora wighitii, for controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin and a method of preparing Gugulipid by agitating the resin in shake flask assembly or sonicating assembly and preparing a solid or a creamy dosage forms.Type: ApplicationFiled: December 22, 2000Publication date: August 29, 2002Inventors: Ram Pratap, Raghwendra Pal, Satyawan Singh, Girja Shankar, Chandeshwar Nath, Hemant Kumar Singh, Depak Raina, Arwind Kumar Srivastava, Anil Kumar Rastogi, Puvvada Ramachandra Murthy, Sudhir Srivastava, Onkar Prasad Asthana, Narendra Singh, Nitya Nand